So..Sarepta can have US rights for $300m upfront and $1 billion in Biobucks @Uboy
Fair enough numbers. Its all for consideration within the context that Roche paid out an upfront of US$750m and US$400m in equity plus up to US$1.7B in regulatory and sales milestones plus royalties - for rights to an ineffective gene therapy outside the US. We do have to remember, however, that in Pharma Land, an anti-inflammatory is Cinderella in the kitchen looking after the chores. It would be unsurprising if you got your wish and Cinderella is off to the Royal Gene Therapy Ball. Charming.
- Forums
- ASX - By Stock
- PER
- Where others have failed will Atl1102 succeed ?
Where others have failed will Atl1102 succeed ?, page-584
-
-
- There are more pages in this discussion • 513 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
(20min delay)
|
|||||
Last
9.0¢ |
Change
0.004(4.65%) |
Mkt cap ! $81.13M |
Open | High | Low | Value | Volume |
8.6¢ | 9.1¢ | 8.5¢ | $181.6K | 2.049M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 10344 | 8.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.0¢ | 64275 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 100000 | 0.085 |
2 | 155000 | 0.084 |
1 | 150000 | 0.083 |
1 | 36585 | 0.082 |
3 | 43077 | 0.081 |
Price($) | Vol. | No. |
---|---|---|
0.090 | 64275 | 1 |
0.091 | 106821 | 1 |
0.092 | 50000 | 1 |
0.094 | 160000 | 1 |
0.095 | 550000 | 2 |
Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online